Clopidogrel hydrogen sulfate CAS 135046-48-9
Introduction：Basic information about Clopidogrel hydrogen sulfate CAS 135046-48-9, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Clopidogrel hydrogen sulfate Basic informationAnti-platelet aggregation drug
| Product Name: | Clopidogrel hydrogen sulfate |
| Synonyms: | PLAVIX;SR-25990C;CLOPIDOGREL BISULPHATE;CLOPIDOGREL HYDROGEN SULPHATE;CLOPIDOGREL SULPHATE;SR-25990C, Plavix, Methyl (+)-(S)-a-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)acetate, Hydrogen sulfate salt;methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate sulfate;(RS)-Clopidogrel bisulfate |
| CAS: | 135046-48-9 |
| MF: | C16H18ClNO6S2 |
| MW: | 419.89 |
| EINECS: | 603-890-4 |
| Product Categories: | Active Pharmaceutical Ingredients;Purinergics P2 receptor;chiral;Intermediates & Fine Chemicals;Pharmaceuticals;API |
| Mol File: | 135046-48-9.mol |
Clopidogrel hydrogen sulfate Chemical Properties
| Melting point | 184°C |
| alpha | D20 +55.10° (c = 1.891 in methanol) |
| storage temp. | 2-8°C |
| solubility | DMSO: ~26mg/mL |
| form | White powder |
| color | white |
| InChI | InChI=1S/C16H16ClNO2S.H2O4S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;1-5(2,3)4/h2-5,7,9,15H,6,8,10H2,1H3;(H2,1,2,3,4) |
| InChIKey | FDEODCTUSIWGLK-RSAXXLAASA-N |
| SMILES | S(O)(O)(=O)=O.C(C1C=CC=CC=1Cl)(N1CCC2SC=CC=2C1)C(=O)OC |
| CAS DataBase Reference | 135046-48-9(CAS DataBase Reference) |
Safety Information
| Safety Statements | 22-24/25 |
| WGK Germany | 3 |
| HazardClass | IRRITANT |
| Storage Class | 8A - Combustible corrosive hazardous materials |
| Hazard Classifications | Aquatic Chronic 2 Eye Dam. 1 Skin Corr. 1B |
| Anti-platelet aggregation drug | Thrombosis caused by arterial atheromatous plaque leads to acute thrombosis cardiovascular and cerebrovascular events. In this pathogenesis, platelets play a central role, which has been fully studied. Clopidogrel hydrogen sulfate is similar to ticlopidine, which is a new anti-platelet aggregation drug, successfully developed by French Sanofi-Synthelabo Fort for the prevention and treatment of heart, brain and other arterial circulation disorders caused by the high blood platelet aggregation, such as recent onset of stroke, myocardial infarction and patients diagnosed with peripheral arterial disease. Many countries have already used it, including United States, Europe and China. This product inhibited platelet activation by inhibiting adenosine diphosphate (ADP) pathway to inhibit platelet aggregation. Since clopidogrel hydrogen sulfate takes several days to achieve effective blood concentration, it does not apply to emergency treatment. Stop using 7 to 10 days, platelet function returned to normal state. The above information is edited by the chemicalbook of Kui Ming. |
| Chemical Properties | Colorless to light yellow liqui |
| Uses | Used as an antithrombotic |
| Uses | rac-Clopidogrel Hydrogen Sulfate is used in the synthesis of Clopidogrel derivatives as platelet aggregation inhibitors. |
| Biochem/physiol Actions | Inhibits ADP-induced platelet aggregation; anti-thrombotic drug. |
Clopidogrel hydrogen sulfate Preparation Products And Raw materials
| Raw materials | Methyl alpha-bromo-2-chlorophenylacetate-->(+/-)-CLOPIDOGREL HYDROCHLORIDE-->4,5,6,7-Tetrahydrothieno[3,2,c] pyridine hydrochloride-->Thiophene-2-ethylamine |
